Creative Medical Technology Holdings Inc falls amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 29 Dec 25
Source: EFFECT
Creative Medical Technology Holdings Inc experienced a significant decline of 10.00%, crossing below its 5-day SMA. This movement occurs as the broader market shows weakness, with the Nasdaq-100 down 0.38% and the S&P 500 down 0.29%.
The drop in CELZ's stock price is attributed to sector rotation, as investors are shifting their focus away from the healthcare sector amid overall market declines. The lack of specific news related to the company further emphasizes the impact of the broader market conditions on its stock performance.
Investors may need to monitor the stock closely for any potential recovery signals or changes in market sentiment that could influence future price movements.
Analyst Views on CELZ
About CELZ
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
